Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BLU2864 是一种具有口服活性的、高选择性的、ATP 竞争性的 PRKACA 抑制剂 ,IC50值为0.3 nM。BLU2864 具有抗肿瘤活性,具有用于癌症和多囊肾的研究潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 995 | 现货 | ||
5 mg | ¥ 2,490 | 现货 | ||
10 mg | ¥ 3,990 | 现货 | ||
25 mg | ¥ 6,390 | 现货 | ||
50 mg | ¥ 8,750 | 现货 | ||
100 mg | ¥ 11,700 | 现货 | ||
500 mg | ¥ 23,600 | 现货 |
产品描述 | BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor with IC 50 of 0.3 nM. BLU2864 exhibits anti-tumor activity. BLU2864 has potential to be used in cancer and polycystic kidney disease research [1] [2]. |
体外活性 | BLU2864 (40 nM and 200 nM; 5 d) shows inhibition of forskolin -induced cystogenesis in vitro[1]. Cell Viability Assay [1] Cell Line: mIMCD3 cells Concentration: 40 nM and 200 nM Incubation Time: 5 days Result: Inhibited forskolin induced in vitro cystogenesis of mIMCD3 cells cultured in Matrigel by 72% and 100% at 40 and 200 nM concentrations, respectively, relative to control. |
体内活性 | BLU2864 (oral gavage; 45 mg/kg; once daily; 5 d) shows inhibition of renal PKA activity in Pkd1 RC/RC mice [1]. BLU2864 (oral gavage; 30 mg/kg; once daily; 5 d) inhibits PKA activity and ameliorates PKD in Pkd1 RC/RC mice [1]. BLU2864 (oral gavage; 30 mg/kg and 75 mg/kg; once daily; 34 d) reduces FLC tumor growth in vivo [2]. Animal Model: Pkd1 RC/RC mice [1] Dosage: 45 mg/kg Administration: Oral gavage; 45 mg/kg; once daily; 5 days Result: Suppressed kidney basal and total PKA activities by 74% and 87% at 3 hours and by 46% and 56% at 15 hours, respectively, in the BLU2864-treated mice compared with controls. Animal Model: Pkd1 RC/RC mice [1] Dosage: 30 mg/kg Administration: Oral gavage; 30 mg/kg; once daily; 5 days Result: Showed higher urine outputs at 15 weeks in the BLU2864-treated mice than in the controls. Showed lower kidney weights, kidney volumes as percent of body weights, and cyst indices. Showed renal basal and total PKA activities by 69% and 84% lower in the BLU2864-treated mice compared with controls. Animal Model: Mice harboring FLC PDX tumors [2] Dosage: 30 mg/kg and 75 mg/kg Administration: Oral gavage; 30 mg/kg and 75 mg/kg; once daily; 34 days Result: Inhibited tumor growth by 48.5% (P=0.003) and by 45.3% (P=0.0005), respectively, at day 34. |
分子量 | 452.43 |
分子式 | C24H19F3N4O2 |
CAS No. | 2810747-89-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (110.51 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2103 mL | 11.0514 mL | 22.1029 mL | 55.2572 mL |
5 mM | 0.4421 mL | 2.2103 mL | 4.4206 mL | 11.0514 mL | |
10 mM | 0.221 mL | 1.1051 mL | 2.2103 mL | 5.5257 mL | |
20 mM | 0.1105 mL | 0.5526 mL | 1.1051 mL | 2.7629 mL | |
50 mM | 0.0442 mL | 0.221 mL | 0.4421 mL | 1.1051 mL | |
100 mM | 0.0221 mL | 0.1105 mL | 0.221 mL | 0.5526 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BLU2864 2810747-89-6 Others BLU-2864 BLU 2864 Inhibitor inhibitor inhibit